Sigmoidoscopy ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	2

97. 潰瘍性大腸炎

---

臨床試験数 : 2,527 /  薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02049502 (ClinicalTrials.gov)	July 2014	27/1/2014	FMT in Ulcerative Colitis-Associated Pouchitis	The Use of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis-associated Pouchitis	Ulcerative Colitis Associated Pouchitis	Biological: biologically active human fecal microbiota;Procedure: sigmoidoscopy	Virginia O. Shaffer	NULL	Completed	18 Years	65 Years	All	8	Phase 2	United States
2	EUCTR2004-000733-12-CZ (EUCTR)	14/07/2004	01/07/2004	A phase III, randomized, multi-center, double-blind, parallel-group, placebo controlled study to evaluate the safety and efficacy of SPD476 (mesalazine) given twice daily (2.4g/day) versus SPD476 given as a single dose (4.8g/day) in subject with acute mild to moderate ulcerative colitis.	A phase III, randomized, multi-center, double-blind, parallel-group, placebo controlled study to evaluate the safety and efficacy of SPD476 (mesalazine) given twice daily (2.4g/day) versus SPD476 given as a single dose (4.8g/day) in subject with acute mild to moderate ulcerative colitis.	Subjects who have newly diagnosed or have a diagnosis of relapsing (relapsessigmoidoscopy score of >1 and a Physician Global Assessment of <2). The original diagnosis of UC must be established by sigmoidoscopy, colonoscopy, or barium enema and have compatible histology.	Product Name: Mesalazine Product Code: SPD476 INN or Proposed INN: Mesalazinum Other descriptive name: 5-amino salicylic acid (5-ASA)	Shire Pharmaceutical Development Inc	NULL	Not Recruiting			Female: yes Male: yes	255	Phase 3	Czech Republic